BLOPEPBOLANG BIOTECHNOLOGY

Triple receptor peptide agonist

Retatrutide

Retatrutide is a synthetic peptide investigated at GIP, GLP-1 and glucagon receptors. The cited phase 2 study examines metabolic outcomes in adults.

BLOPEP vial — representative image
Representative image
Quantity per vial

Select variantCompare prices and choose a variant to set the quantity and add it to your quote.

Subtotal excludes freight and taxes. Availability and final terms are confirmed in the quote. Commercial and shipping terms

Mechanism and findings →

Mechanism and findings

Human study · Study formulation · 338 adults with obesity or overweight and a weight-related condition

Body-weight endpoint

The randomized phase 2 trial evaluated weight change over 48 weeks; gastrointestinal events and dose-dependent heart-rate increases were reported.

Jastreboff et al., 2023 →

Literature findings; refer to the model and formulation studied.

Mechanism of action

Retatrutide — triple receptor peptide agonist. The literature identity must be matched to the documented chemical form and composition of the supplied material.

The molecule combines agonism at GIP, GLP-1 and glucagon receptors. The phase 2 trial analyzed exposure and weight change, with a primary endpoint at 24 weeks and follow-up through 48 weeks. Groups, comparators and adverse events are necessary to interpret any weight-reduction value.

  • GLP-1R / GIPR / GCGR

Jastreboff et al., 2023

Studied findings 1
Human study · Study formulation

Body-weight endpoint

338 adults with obesity or overweight and a weight-related condition

The randomized phase 2 trial evaluated weight change over 48 weeks; gastrointestinal events and dose-dependent heart-rate increases were reported.

View context
Study design
Original-study abstract; experimental design described in linked source
Sample scope / arm
Not extracted; consult original study
Comparator
See original-study context
Experimental context (not instructions for use)
Abstract-level extraction; full methods and tables still require review.
Source section / table / abstract
Abstract

Evidence concerns the studied material and model, not the supplied BLOPEP batch.

Jastreboff et al., 2023

Sources and studies 1Peptide Monographs
  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

    Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML, · 2023 · The New England journal of medicine

    DOI: 10.1056/nejmoa2301972

Specifications and packaging

Nominal variant content; analytical results belong to the documented batch.

Material type
Peptide

Quality and analyses

Review specifications, analytical results and documentation for published batches.

Purity
>99%
Type
Declared specification

Published batches

Batch results have not yet been published on this page.

Look up batch

Storage

Consult the specific conditions in the supplied material documentation.

Delivery and commercial terms

Freight, timing and import terms will be confirmed in the quote for the selected destination.

Other materials in this area

View category →